- Diabetic assays, encompassing a range of diagnostic tools used to detect and monitor biomarkers such as glucose, insulin, and HbA1c, are increasingly essential components of modern diabetes management in both clinical and homecare settings due to their enhanced accuracy, rapid results, and compatibility with automated and point-of-care systems
- The escalating demand for diabetic assays is primarily fueled by the growing global burden of diabetes, increasing awareness of early diagnostic testing, and the proliferation of technologically advanced diagnostic platforms that facilitate efficient and frequent monitoring
- North America dominates the diabetic assays market with the largest revenue share of 38.5% in 2024, characterized by a high prevalence of diabetes, advanced healthcare infrastructure, and strong support from governmental and private organizations promoting early detection and disease management
- Asia-Pacific is expected to be the fastest growing region in the diabetic assays market during the forecast period due to increasing diabetic population, improving access to healthcare diagnostics, and rising awareness of the importance of routine blood glucose and HbA1c testing
- Enzymatic Assay segment dominates the diabetic assays market with a market share of 45.5% in 2024, driven by its high sensitivity, accuracy, and widespread adoption in clinical diagnostics for glucose and HbA1c testing
